Want to see NKTX full AI Analyst Report?
NKTX Stock Chart & Stats
$2.63
-$0.01(-0.44%)
At close: 4:00 PM EDT
$2.63
-$0.01(-0.44%)
Day’s Range― - ―
52-Week Range$1.70 - $3.72
Previous Close$2.28
Volume807.02K
Average Volume (3M)570.53K
Market Cap
$209.14M
Enterprise Value$101.60
Total Cash (Recent Filing)$182.76M
Total Debt (Recent Filing)$73.54M
Price to Earnings (P/E)―
Beta1.78
Next Earnings
Nov 11, 2026EPS Estimate
-0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.57
Shares Outstanding71,624,794
10 Day Avg. Volume484,670
30 Day Avg. Volume570,527
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)0.44
Price to Sales (P/S)0.00
P/FCF Ratio-1.52
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$11.75Price Target Upside346.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.59
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Off-the-shelf NK PlatformAn off-the-shelf allogeneic approach may simplify treatment logistics and broaden scalability compared with patient-specific manufacturing. If clinical efficacy is demonstrated, this platform design could support more consistent delivery and wider adoption across cancer indications over time.
Moderate LeverageModerate leverage provides a stronger financial foundation than a highly debt-dependent balance sheet would offer. It may preserve some flexibility for funding research and development, although operating losses and declining equity remain important constraints on that capacity.
Governance OversightRegular director elections, auditor ratification, and annual say-on-pay voting reinforce formal shareholder oversight. This governance structure can support accountability and more consistent monitoring of executive decisions as the company advances its clinical pipeline and allocates capital.
Bears Say
Pre-revenue BusinessThe absence of commercial revenue leaves Nkarta dependent on clinical progress and external funding rather than an established operating franchise. Until a product is approved and generates sales, the company lacks recurring revenue to offset research costs or validate its business model.
Persistent Cash BurnMaterially negative operating and free cash flow means ongoing research consumes substantial capital without internally generated funding. Continued reliance on financing can constrain strategic flexibility and expose the company to dilution or funding pressure before revenues emerge.
Declining Equity BaseShrinking equity alongside deeply negative returns indicates that losses are eroding the capital base over time. This reduces financial resilience, limits the resources available for development, and can increase dependence on future capital raises to sustain operations.
Nkarta News
NKTX FAQ
What was Nkarta’s price range in the past 12 months?
Nkarta lowest stock price was $1.70 and its highest was $3.72 in the past 12 months.
What is Nkarta’s market cap?
Nkarta’s market cap is $209.14M.
When is Nkarta’s upcoming earnings report date?
Nkarta’s upcoming earnings report date is Nov 11, 2026 which is in 64 days.
How were Nkarta’s earnings last quarter?
Nkarta released its earnings results on Aug 10, 2026. The company reported -$0.54 earnings per share for the quarter, missing the consensus estimate of -$0.36 by -$0.18.
Is Nkarta overvalued?
According to Wall Street analysts Nkarta’s price is currently Undervalued.
Does Nkarta pay dividends?
Nkarta does not currently pay dividends.
What is Nkarta’s EPS estimate?
Nkarta’s EPS estimate is -0.4.
How many shares outstanding does Nkarta have?
Nkarta has 71,624,794 shares outstanding.
What happened to Nkarta’s price movement after its last earnings report?
Nkarta reported an EPS of -$0.54 in its last earnings report, missing expectations of -$0.36. Following the earnings report the stock price went down -5.285%.
Which hedge fund is a major shareholder of Nkarta?
Currently, no hedge funds are holding shares in NKTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nkarta Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.75 (346.77% Upside)
$11.75 (346.77% Upside)
Blogger Sentiment
Bullish
NKTX Sentiment 100%
Sector Average 60%
Sector Average 60%
Hedge Fund Trend
Increased
By 587.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 2.4%
Last 30 Days ▲ 2.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
37.08%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-24.69%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Nkarta
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
NKTX Stock 12 Month Forecast
Average Price Target
$11.75
▲(346.77% Upside)
Technical Analysis
Ownership Overview
20.62% Insiders
7.76% Mutual Funds
46.00% Other Institutional Investors
18.48% Public Companies and
Individual Investors